Immunomedics, Inc. (IMMU) Release: Scientific Data On Epratuzumab In Systemic Lupus Erythematosus To Be Presented At EULAR 2014
6/9/2014 9:11:24 AM
MORRIS PLAINS, N.J., June 9, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that scientific data on epratuzumab, an investigational therapy for the treatment of systemic lupus erythematosus (SLE), also known as lupus, will be presented at the European League Against Rheumatism (EULAR) 2014 Annual Congress to be held in Paris, France, from June 11 – 14, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by